Posted by Michael Wonder on 26 Feb 2020
UK NICE to announce decision on Vertex’s therapy Trikafta in December
26 February 2020 - NICE is currently in the process of evaluating Vertex Pharmaceuticals’ triple combination therapy — known as Trikafta in the United States — for the treatment of cystic fibrosis.
The institute expects to deliver its recommendation on 16 December 2020.
NICE has the responsibility of giving advice to the National Health Services in England on whether new therapies should be made available for physicians to prescribe. NICE’s advice is also largely followed by the health authorities in Northern Ireland and Wales.
